Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CZZLF$0.240.00(0.00%)Cizzle Brands Accelerates U.S. National Exchange Listing Strategy to Drive Institutional Growth and Unlock Shareholder Value[8:30:00 PM ET]IMMFF$1.100.00(0.00%)Omni Bridgeway Makes Strong Start to FY27 with 3.9x MOIC on Completions and US$1 Billion Series II Final Close[8:19:28 PM ET]HRTX$0.30+0.00(+0.40%)Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026[8:09:52 PM ET]CPAC$12.77+0.04(+0.31%)Cementos Pacasmayo S.A.A. Announces Consolidated Results for Third Quarter 2026[8:04:00 PM ET]INM$1.58+0.14(+10.06%)InMed Announces CVR Distribution Record Date in Connection with Proposed Merger[8:01:00 PM ET]DSGR$35.010.00(0.00%)Distribution Solutions Group Completes Strategic Acquisition of Winzer and FastServ Supply[8:00:00 PM ET]BGDFF$0.60+0.03(+4.44%)Mining Exploration Entity or Oil and Gas Exploration Entity Quarterly Cash Flow Report[8:00:00 PM ET]HCM$14.27-0.09(-0.63%)Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer[8:00:00 PM ET]WDAY$207.49-2.50(-1.19%)Firms in Asia Pacific Embrace Unified Workday Platforms[8:00:00 PM ET]AGLDF$0.10-0.02(-16.67%)Austral Gold Files Q3 2026 Quarterly Activities Report[7:50:00 PM ET]LVS$36.57+0.89(+2.49%)SANDS CHINA ANNOUNCES OFFERING OF SENIOR UNSECURED NOTES Las Vegas Sands Corp. (NYSE: LVS) today announced that its majority-owned subsidiary, Sands China Ltd. ("Sands China"), intends to offer...[7:47:00 PM ET]CCEYF$0.18-0.08(-29.75%)CanCambria Energy Grants Stock Options[7:30:00 PM ET]

TENX · NASDAQ

Tenax Therapeutics, Inc.

$1.68 -0.04 (-2.27%)

Company overview

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan), which have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$44.6M
Employees
4
Headquarters
Chapel Hill, NC
Website
tenaxthera.com
CEO
Christopher T. Giordano
Listed
April 4, 1994
P/E
-1.19
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$61.6M
EBITDA
-$58.8M
Net income
-$57.9M
EPS
-$1.41
Total assets
$123M
Total debt
$0.00
Earnings yield
-83.93%

Price chart

0.595.4710.3515.2420.12
TENX 1D NASDAQ O1.70H1.70L1.62C1.64-0.08 (-4.94%)Vol295.36K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
TENXTenax Therapeutics, Inc. Legal Pomerantz Law Firm Announces The Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers - TENX ACCESS Newswire
TENXTenax Therapeutics, Inc. Stock news Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Director Buys $101,760.00 in Stock Defense World
TENXTenax Therapeutics, Inc. Press release Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference GlobeNewswire
TENXTenax Therapeutics, Inc. Press release Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 GlobeNewsWire
TENXTenax Therapeutics, Inc. Legal Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky GuruFocus
TENXTenax Therapeutics, Inc. Legal Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky PRNewsWire
TENXTenax Therapeutics, Inc. Legal Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX) GlobeNewsWire
TENXTenax Therapeutics, Inc. Legal TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law GuruFocus
TENXTenax Therapeutics, Inc. Legal TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law Business Wire
TENXTenax Therapeutics, Inc. Legal TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) Business Wire
TENXTenax Therapeutics, Inc. Legal Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX) PRNewsWire
TENXTenax Therapeutics, Inc. Stock news Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case MarketBeat
TENXTenax Therapeutics, Inc. Stock news Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback Benzinga
TENXTenax Therapeutics, Inc. Stock news Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript Seeking Alpha
TENXTenax Therapeutics, Inc. Stock news Tenax Therapeutics' heart drug misses main goal in study, shares plunge Reuters
TENXTenax Therapeutics, Inc. Press release Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF GlobeNewsWire
TENXTenax Therapeutics, Inc. Stock news Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know Zacks Investment Research
TENXTenax Therapeutics, Inc. Stock news Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead Seeking Alpha
TENXTenax Therapeutics, Inc. Press release Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 GlobeNewsWire
TENXTenax Therapeutics, Inc. Press release Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
See more
FAQ

Questions about Tenax Therapeutics, Inc.

What does Tenax Therapeutics, Inc. do?
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan), which have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
What is TENX's market cap?
Tenax Therapeutics, Inc. (TENX) is a listed stock with a live quote. The latest market cap on this page is $44.6M.
Where is Tenax Therapeutics, Inc. headquartered?
Tenax Therapeutics, Inc. is headquartered in Chapel Hill, NC.
How do I get TENX news from the API?
Call GET /v1/news?tickers=TENX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does TENX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for TENX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the TENX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs